Thoracic Malignancies

Vanderbilt

Questions discussed in this category

For patients with KRAS G12C mutated NSCLC, how would you decide between using targeted therapy with sotorasib vs adagrasib?

Is there anything to differentiate the two agents? CNS penetration reportedly with adagrasib, FDA accelerated approval has been given with sotorasib.&...

2 Answers available

What is the role for "liquid biopsy" for patients with newly diagnosed metastatic NSCLC?

5 Answers available

Outside of a clinical trial, what is your preferred third-line systemic therapy option for a patient with relapsed/refractory ES-SCLC?

1 Answer available

In a life-time non-smoker with stage IV lung adenocarcinoma presenting in visceral crisis, what therapy would you recommend to avoid organ failure while awaiting mutational status?

1 Answer available

What is the optimal treatment strategy for patients with stage IV NSCLC who have an actionable molecular target identified after initiation of first-line systemic therapy?

1 Answer available

Would you consider checkpoint inhibitor therapy alone in a patient with metastatic NSCLC with PDL-1 < 1% who is otherwise refusing chemotherapy?

Would nivo + Ipi be appropriate in this situation, especially if high TMB?

4 Answers available

With the FDA approval of third line pembrolizumab for patients with SCLC, how would you select a candidate for pembrolizumab or nivolumab in the third line management of SCLC?

0 Answers available

When do you recommend broader molecular testing for clinical trials in stage IV NSCLC patients who have negative initial molecular testing for FDA-approved targetable mutations?

0 Answers available

Papers discussed in this category

N. Engl. J. Med., 2019 Sep 28

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Am Soc Clin Oncol Educ Book,

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.

Ann Oncol, 2013 Mar 01

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

N Engl J Med, 2022 Jun 03

Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.

Oncology, 2020 May 28

The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Jun 16

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With -Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.

Thoracic Malignancies

Vanderbilt

Questions discussed in this category

Papers discussed in this category

Related Topics in Thoracic Malignancies